Skip to main content
Clinical Trials/IRCT138807112539N1
IRCT138807112539N1
Completed
Phase 3

A comparative evaluation of combination therapy of Lamivudine and Colchicine comparing with Lamivudine and placebo in clinical and laboratory improvement of chronic hepatitis B

Arak University of Medical Sciences0 sites100 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Arak University of Medical Sciences
Enrollment
100
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • positive HBS Ag, confirmed chronic hepatitis B, ALT level at least twofold of normal range
  • Exclusion criteria: positive HCV Ab, positive HIV Ab, Alcohol abuse, Presence of auto immune hepatitis, metabolic liver disease, right cardiac failure or pulmonary hypertension, low compliance, allergic reaction to drugs or sever side effect of drugs, presence of decompensate cirrhosis (PT\>20 sec and ALb\<3 gr/dl)

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials